This webinar will review the regulatory requirements for investigating an OOS Investigation. The responsibilities of the analyst, the supervisor and QA will be discussed. A detailed flow chart will be used to help the attendees clearly understand the steps and the order in which they are to be performed. The structure of an Investigation report which properly documents the investigation will be discussed.
WHY SHOULD YOU ATTEND?
The lack of or Inadequate procedures for handling out of specification (OOS) situations and failure investigations are amongst the most frequently found deviations in FDA warning letters.
Most companies have procedures but either they are not adequate or are not followed. This seminar will guide attendees through the entire process from detection an out-of-specification result to informal and formal laboratory and batch investigations.
AREA COVERED
- Phase I- Laboratory Phase of Investigations
- Phase II a Full Scale Investigation
- Concluding an Investigation
- Out-of Trend investigations
- Common pitfalls during OOS Investigations
- Review of recent OOS related citations in Warning Letters
LEARNING OBJECTIVES
- Benefits: The lack of or Inadequate procedures for handling out of specification (OOS) situations and failure investigations are amongst the most frequently found deviations in FDA warning letters.
- Most companies have procedures but either they are not adequate or are not followed. This seminar will guide attendees through the entire process from detection an out-of-specification result to informal and formal laboratory and batch investigations.
- Complimentary Hand-outs (other than ppt slides): For e.g. checklists, process documents, flow charts, pdf or docs of supplementary reading material, etc.
WHO WILL BENEFIT?
- Quality Assurance/Quality Control Directors, Managers, and Specialists
- Regulatory Affairs/Regulatory Compliance Directors, Managers, and Specialists
- Quality Control Laboratory Staff
The lack of or Inadequate procedures for handling out of specification (OOS) situations and failure investigations are amongst the most frequently found deviations in FDA warning letters.
Most companies have procedures but either they are not adequate or are not followed. This seminar will guide attendees through the entire process from detection an out-of-specification result to informal and formal laboratory and batch investigations.
- Phase I- Laboratory Phase of Investigations
- Phase II a Full Scale Investigation
- Concluding an Investigation
- Out-of Trend investigations
- Common pitfalls during OOS Investigations
- Review of recent OOS related citations in Warning Letters
- Benefits: The lack of or Inadequate procedures for handling out of specification (OOS) situations and failure investigations are amongst the most frequently found deviations in FDA warning letters.
- Most companies have procedures but either they are not adequate or are not followed. This seminar will guide attendees through the entire process from detection an out-of-specification result to informal and formal laboratory and batch investigations.
- Complimentary Hand-outs (other than ppt slides): For e.g. checklists, process documents, flow charts, pdf or docs of supplementary reading material, etc.
- Quality Assurance/Quality Control Directors, Managers, and Specialists
- Regulatory Affairs/Regulatory Compliance Directors, Managers, and Specialists
- Quality Control Laboratory Staff
Speaker Profile
Danielle DeLucy
Danielle DeLucy, MS, is owner of ASA Training and Consulting, LLC which provides Pharmaceutical and Biologics based companies with training and quality systems assistance in order to meet Regulatory compliance. Prior to this role, Danielle has been in the industry for 15 years serving in numerous Quality Management Roles, such as the Director of Product Quality, the oversight of Sterility Assurance practices and provided QA oversight of numerous filling and packaging operations. Danielle began her QA career as a Quality Control Pharmaceutical Microbiologist at a contract laboratory where she performed various tests for their clients. In the years after, she …
Upcoming Webinars
Effective Communication: Ensuring Clarity, Accountability a…
2-Hour Virtual Seminar on Workplace Investigations 101: How…
AI for Excel Professionals: Enhancing Productivity with Cha…
Employers Should Prepare for Immigration Raids in 2026! Thi…
The Importance of the first 5 seconds when presenting
Negotiating Skills For Professional Results - Winning Strat…
Validation Statistics for Non-Statisticians
Workplace Behavior in 2026: Tackling Conflicts and Incivili…
FDA Recommendations for Artificial Intelligence/Machine Lea…
Interactive dashboards & analytics in Excel
Bootcamp for New Managers and Supervisors: Develop These Es…
Enhancing Project Management with Storytelling Techniques
4-Hour Workshop on Data Simplified: Sorting and Filtering, …
Creating Your 2026 Marketing Strategy
The Language of Leadership: Is Your Communication Style As …
ChatGPT for Innovative Business Advisory Services for Accou…
Utilizing A Proven Process When Conducting Sensitive, Inter…
How to Write Procedures to Avoid Human Errors
Human Factors Usability Studies Following ISO 62366 and FDA…
Why EBITDA Doesn't Spell Cash Flow and What Does?
Mastering DAX Patterns in the Era of AI & Copilot
Establishing Appropriate Quality Metrics and Key Performanc…
IRS Form 1099 Reporting: Compliance Requirements
FDA QMSR Explained: How the QMSR Replaces the QSR
How to Manage the Legal Landmine of the FMLA, ADA and Worke…
Understanding EBITDA – Definition, Formula & Calculation
Tattoos, hijabs, piercings, and pink hair: The challenges …
FDA Compliance And Laboratory Computer System Validation
Medical Device Hazard analysis following ISO 14971
Excel Spreadsheets; Develop and Validate for 21 CFR Part 11…
Excel + AI: The Smart User's Guide to Faster, Easier Work w…